You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Huge Alerts.

CEO and Chairman of BioStem Technologies (OTC: BSEM) has been honored as 2025 Florida Entrepreneur of The Year® Winner by Ernst & Young – a prestigious recognition that could propel BSEM to national and global stages while elevating patience care and setting new standards in MedTech excellence.

The future belongs to regenerative medicine, and BioStem Technologies (OTC: BSEM) is emerging as a trailblazer driving innovation, rapid revenue growth, and groundbreaking advancements. This expanding MedTech company utilizes the unique healing properties of perinatal tissue to develop, produce, and bring to market allografts designed for regenerative therapies in advanced wound care.

At the heart of BSEM’s approach is its proprietary BioREtain® processing technology, enabling the creation of life-changing products that deliver meaningful patient outcomes. Several positive news announcements are reflecting the tremendous growth potential of BSEM. This includesrecently announcing record preliminary net revenue of $72.5 million for Q1 2025. This is a 73% increase compared to $41.9 million in Q1 2024. The company also ended the quarter with cash on hand at $26.7 million, an increase from $22.8 million on December 31st, 2024.

This was the strongest first quarter in the company’s history! On the capital markets front, BSEM remains in active review with the SEC regarding its Form 10 registration and uplisting process, and it looks forward to completing this milestone and becoming listed on Nasdaq. Being listed on the NASDAQ would open up the stock to new investors, especially on the institutional front!

Not long ago Jason Matuszewski, CEO and Chairman of the Board of BSEM was named an Entrepreneur Of The Year 2025 Florida Award winner! Winning the Entrepreneur of The Year® Florida Award highlights the company’s leadership, showcasing his ability to steer BSEM with vision and purpose.

For investors, this signals that the company is led by a proven, respected entrepreneur who has been independently vetted for driving meaningful growth and innovation—an important indicator of the company’s potential for long-term success.

Matuszewski now advances to the national Entrepreneur of The Year® competition this fall, with a chance to represent the U.S. on the global stage in 2026. As he moves forward, the company will benefit from ongoing exposure through Ernst & Young’s network, events, and media. Combined with BSEM’s existing product pipeline and potential FDA-related milestones. This creates a powerful narrative that may help sustain momentum, both fundamentally and in the stock price. This award is not just an honor—it’s a strategic asset that validates BSEM’s mission, leadership, and investment case at a critical stage in the company’s growth trajectory.

See why Zack’s Small Cap Research has issued a $35.50 price target on BSEM shares!

Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431

We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security.

We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of BioStem Technologies Inc. (OTC: BSEM) . The compensation consists of up to $2,500 and was received/will be received from Sideways Frequency.

This compensation should not be considered as an endorsement of the securities of BioStem Technologies Inc. (OTC: BSEM) and we are not responsible for any errors or omissions in any information provided about the securities of BioStem Technologies Inc. (OTC: BSEM) by Huge Alerts.

We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions.

This disclosure is made as of 7/16/2025.

Behind the Markets

Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.

You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here.

Today's Bonus Content: 3 Dirt-Cheap Stocks You Can’t Afford to Ignore

(By clicking this link you agree to receive emails from Trading Tips and our affiliates. You can opt out at any time.)